World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
31070
World Ranking
13076
National Ranking
6677

Philip A. Philip publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Philip A. Philip sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 549 publications — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Philip A. Philip D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Philip A. Philip sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 88 D-Index — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Philip A. Philip is affiliated with Wayne State University in the United States and has a research focus spanning medicine and biochemistry, genetics, and molecular biology. Their academic contributions are primarily concentrated in oncology, with significant work also in molecular biology, cancer research, pulmonary and respiratory medicine, and surgery.

Their research topics cover a range of areas within oncology and cancer biology. These include pancreatic and hepatic oncology research, cancer genomics and diagnostics, colorectal cancer treatments and studies, genetic factors in colorectal cancer, neuroendocrine tumor research advances, gastric cancer management and outcomes, and cholangiocarcinoma and gallbladder cancer studies.

Philip A. Philip has published extensively in several prominent scientific journals. Frequent venues for their work include the Journal of Clinical Oncology, Cancer Research, Cancer and Metastasis Reviews, Clinical Cancer Research, and Cancers.

Notable recent papers authored by Philip A. Philip include:

  • Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study (2021), published in The Lancet. Gastroenterology & Hepatology
  • Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406) (2020), published in Journal of Clinical Oncology
  • Neoadjuvant therapy for pancreatic cancer (2023), published in Nature Reviews Clinical Oncology
  • Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma (2021), published in JAMA Oncology
  • Metastatic Pancreatic Cancer: ASCO Guideline Update (2020), published in Journal of Clinical Oncology

Frequent collaborators in their research include:

  • Anthony F. Shields
  • Asfar S. Azmi
  • Mohammed Najeeb Al Hallak
  • Md. Hafiz Uddin
  • Amro Aboukameel

Best Publications

  • Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial

    Charles S. Fuchs;Toshihiko Doi;Raymond W. Jang;Raymond W. Jang;Kei Muro

  • Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    Kohei Shitara;Mustafa Özgüroğlu;Yung-Jue Bang;Maria Di Bartolomeo

  • Up-regulation of miR-200 and let-7 by Natural Agents Leads to the Reversal of Epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer Cells

    Yiwei Li;Timothy G. VandenBoom;Dejuan Kong;Zhiwei Wang

  • Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

    Philip A. Philip;Jacqueline Benedetti;Christopher L. Corless;Ralph Wong

  • Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

    Philip J. Johnson;Shukui Qin;Joong Won Park;Ronnie T.P. Poon

  • Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

    Milind Javle;Maeve Lowery;Rachna T. Shroff;Karl Heinz Weiss

  • Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer

    Philip A. Philip;Michelle R. Mahoney;Cristine Allmer;James Thomas

  • Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.

    Shadan Ali;Aamir Ahmad;Sanjeev Banerjee;Subhash Padhye

  • miR-146a suppresses invasion of pancreatic cancer cells

    Yiwei Li;Timothy G. VandenBoom;Zhiwei Wang;Dejuan Kong

  • Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.

    Eileen M. O'Reilly;Do Youn Oh;Neesha Dhani;Daniel J. Renouf

  • Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.

    Matthew H.G. Katz;Qian Shi;Syed A. Ahmad;Joseph M. Herman

  • Inactivation of Nuclear Factor κB by Soy Isoflavone Genistein Contributes to Increased Apoptosis Induced by Chemotherapeutic Agents in Human Cancer Cells

    Yiwei Li;Fakhara Ahmed;Shadan Ali;Philip A. Philip

  • Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)

    Scott Kopetz;Katherine A. Guthrie;Van K. Morris;Heinz Josef Lenz

  • Phase II Study of Erlotinib in Patients With Advanced Biliary Cancer

    Philip A. Philip;Michelle R. Mahoney;Cristine Allmer;James Thomas

  • Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

    Davendra P.S. Sohal;Pamela B. Mangu;Alok A. Khorana;Manish A. Shah

  • Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design

    Matthew Harold Katz;Robert Marsh;Joseph M. Herman;Qian Shi

  • Molecular Evidence for Increased Antitumor Activity of Gemcitabine by Genistein In vitro and In vivo Using an Orthotopic Model of Pancreatic Cancer

    Sanjeev Banerjee;Yuxiang Zhang;Shadan Ali;Mohammad Bhuiyan

  • Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.

    Sam J. Lubner;Michelle R. Mahoney;Jill L. Kolesar;Noelle K. LoConte

  • Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313

    Ramesh K. Ramanathan;Shannon L. McDonough;Philip A. Philip;Sunil R. Hingorani

  • Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.

    Milind Javle;Sameek Roychowdhury;Robin Kate Kelley;Saeed Sadeghi

Frequent Co-Authors

Fazlul H. Sarkar
Fazlul H. Sarkar Wayne State University
Heinz-Josef Lenz
Heinz-Josef Lenz University of Southern California
Richard M. Goldberg
Richard M. Goldberg West Virginia University
Eileen M. O’Reilly
Eileen M. O’Reilly Memorial Sloan Kettering Cancer Center
Andrew M. Lowy
Andrew M. Lowy University of California, San Diego
Wafik S. El-Deiry
Wafik S. El-Deiry Brown University
Yiwei Li
Yiwei Li Wayne State University
Jordan Berlin
Jordan Berlin Vanderbilt University Medical Center
Sanjeev Banerjee
Sanjeev Banerjee Wayne State University
David Goldstein
David Goldstein University of New South Wales

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in medical careers beyond the traditional M.D. route? Online health degrees offer flexible options for both entry-level and advanced learners. For nurses looking to advance, dnp online programs cheap make it possible to earn a Doctor of Nursing Practice while saving on tuition and managing work commitments.

Pharmacists are also in high demand, and pursuing an online pharmacy degree can be a cost-effective path to entering this respected field. Those interested in the fast-growing field of health data can explore a him degree online for roles in managing digital health records and information systems.

For students looking for a quick entry point into healthcare, medical billing and coding is a smart choice. Learning about the average cost of medical billing and coding program can help you plan your education and budget.

Each of these online pathways can prepare you for a rewarding healthcare career without stepping foot on campus.

Best Scientists Citing Philip A. Philip

Trending Scientists

Recently Published Articles